JP2021519589A - インターロイキン１７ａ（ｉｌ−１７ａ）に結合する抗体を用いた自己免疫障害及び炎症障害の治療 - Google Patents

インターロイキン１７ａ（ｉｌ−１７ａ）に結合する抗体を用いた自己免疫障害及び炎症障害の治療 Download PDF

Info

Publication number
JP2021519589A
JP2021519589A JP2020552838A JP2020552838A JP2021519589A JP 2021519589 A JP2021519589 A JP 2021519589A JP 2020552838 A JP2020552838 A JP 2020552838A JP 2020552838 A JP2020552838 A JP 2020552838A JP 2021519589 A JP2021519589 A JP 2021519589A
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
antigen
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020552838A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019191563A5 (https=
JP2021519589A5 (https=
Inventor
ジェイ． カルツォーネ，フランク
ジェイ． カルツォーネ，フランク
ファン，メイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remd Biotherapeutics Inc
Original Assignee
Remd Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remd Biotherapeutics Inc filed Critical Remd Biotherapeutics Inc
Publication of JP2021519589A publication Critical patent/JP2021519589A/ja
Publication of JPWO2019191563A5 publication Critical patent/JPWO2019191563A5/ja
Publication of JP2021519589A5 publication Critical patent/JP2021519589A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020552838A 2018-03-29 2019-03-29 インターロイキン１７ａ（ｉｌ−１７ａ）に結合する抗体を用いた自己免疫障害及び炎症障害の治療 Pending JP2021519589A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649854P 2018-03-29 2018-03-29
US62/649,854 2018-03-29
PCT/US2019/024794 WO2019191563A1 (en) 2018-03-29 2019-03-29 Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)

Publications (3)

Publication Number Publication Date
JP2021519589A true JP2021519589A (ja) 2021-08-12
JPWO2019191563A5 JPWO2019191563A5 (https=) 2022-03-29
JP2021519589A5 JP2021519589A5 (https=) 2022-03-29

Family

ID=68058546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552838A Pending JP2021519589A (ja) 2018-03-29 2019-03-29 インターロイキン１７ａ（ｉｌ−１７ａ）に結合する抗体を用いた自己免疫障害及び炎症障害の治療

Country Status (5)

Country Link
US (1) US20210079087A1 (https=)
EP (1) EP3773717A4 (https=)
JP (1) JP2021519589A (https=)
CN (1) CN112203685A (https=)
WO (1) WO2019191563A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507988A (ja) * 2004-08-05 2008-03-21 ノバルティス アクチエンゲゼルシャフト Ｉｌ−１７拮抗性抗体
JP2009540018A (ja) * 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
JP2009540824A (ja) * 2006-06-23 2009-11-26 アストラゼネカ アクチボラグ ヒトｉｌ−１７に対する抗体分子
JP2010500028A (ja) * 2006-08-11 2010-01-07 シェーリング コーポレイション Ｉｌ−１７ａに対する抗体
JP2013509193A (ja) * 2009-10-30 2013-03-14 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−１７ａ拮抗物質
JP2016508508A (ja) * 2013-02-08 2016-03-22 ノバルティス アーゲー 抗ｉｌ−１７ａ抗体ならびに自己免疫性および炎症性障害の処置におけるその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100455599C (zh) * 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
US20040005615A1 (en) * 2002-05-24 2004-01-08 Jing Li Amplification and overexpression of oncogenes
DE10256900A1 (de) * 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
WO2014140368A1 (en) * 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507988A (ja) * 2004-08-05 2008-03-21 ノバルティス アクチエンゲゼルシャフト Ｉｌ−１７拮抗性抗体
JP2009540018A (ja) * 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
JP2009540824A (ja) * 2006-06-23 2009-11-26 アストラゼネカ アクチボラグ ヒトｉｌ−１７に対する抗体分子
JP2010500028A (ja) * 2006-08-11 2010-01-07 シェーリング コーポレイション Ｉｌ−１７ａに対する抗体
JP2013509193A (ja) * 2009-10-30 2013-03-14 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−１７ａ拮抗物質
JP2016508508A (ja) * 2013-02-08 2016-03-22 ノバルティス アーゲー 抗ｉｌ−１７ａ抗体ならびに自己免疫性および炎症性障害の処置におけるその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.INFLAMMATION RES.,2016, VOL. 9, PP. 39-50, JPN6023007619, ISSN: 0005000822 *

Also Published As

Publication number Publication date
EP3773717A4 (en) 2022-05-11
CN112203685A (zh) 2021-01-08
US20210079087A1 (en) 2021-03-18
WO2019191563A1 (en) 2019-10-03
EP3773717A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
JP7100731B2 (ja) ヒトｉｌ－４受容体に対する高親和性ヒト抗体
US11319372B2 (en) Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
CN110337448B (zh) 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法
CN107074943B (zh) I型干扰素受体抗体及其用途
CN110669135B (zh) 一种双特异性抗体及其用途
JP2021526022A (ja) 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
RU2605595C2 (ru) Антитела против g-csfr и их применение
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
CN101522716A (zh) 抗人il-4受体的高亲和力人抗体
JP2024513921A (ja) 抗ｃｄ１２２抗体及びその使用
US11248049B2 (en) Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)
JP7689116B2 (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
US20260109770A1 (en) C-c chemokine receptor type 8 (ccr8) antagonist antibodies
WO2021216832A1 (en) Chemokine receptor 4 (cxcr4) antagonist antibodies
KR20210007041A (ko) 항-gm-csf 항체 및 이것의 사용
JP2021518748A (ja) カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体
JP2021519589A (ja) インターロイキン１７ａ（ｉｌ−１７ａ）に結合する抗体を用いた自己免疫障害及び炎症障害の治療
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231003